LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21
Chapter 11•Systemic Therapy for Cancer 133continued treatment may result in coma. Retreatment with subsequent
doses of IL-2 is contraindicated in patients with repetitive or refractory
seizures.Answer 11.24. The answer is D.
Bevacizumab was the first angiogenesis inhibitor to be approved by the
FDA for cancer treatment following a phase III trial showing a survival
benefit. Drugs that only exhibit antiangiogenic properties are known as
exclusive inhibitors. Drugs such as vorinostat, celecoxib, and bortezomib
all inhibit angiogenesis as a secondary function and thus are known as
inclusive inhibitors. Proangiogenic factors include, but are not limited to,
vascular endothelial growth factor, platelet-derived growth factor, placen-
tal growth factor, and transforming growth factor-.Answer 11.25. The answer is B.
The National Comprehensive Cancer Network breast cancer guidelines
recommend the use of single-agent aromatase inhibitor therapy for 5 years
as adjuvant endocrine therapy for postmenopausal patients. The use of
tamoxifen alone for 5 years is limited to those who decline or have a
contraindication to aromatase inhibitors. LHRH agonists should not be
used in postmenopausal patients. The antiandrogen bicalutamide is not
used to treat breast cancer.